1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Psoriatic Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017


DelveInsight’s Report, “Psoriatic Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Psoriatic Arthritis Report is to understand the market and pipeline status of the drugs around the Psoriatic Arthritis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Psoriatic Arthritis. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Psoriatic Arthritis.
- A review of the marketed products under prescription for Psoriatic Arthritis, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Psoriatic Arthritis with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Psoriatic Arthritis drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Psoriatic Arthritis drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Psoriatic Arthritis drugs.
- Coverage of Psoriatic Arthritis Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy:
- Evaluate the marketing status and exclusivity details of Psoriatic Arthritis key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Psoriatic Arthritis.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Psoriatic Arthritis.
- API intelligence over marketed drugs forPsoriatic Arthritisand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Psoriatic Arthritis.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Psoriatic Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
Illustrative
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Psoriatic Arthritis
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Psoriatic Arthritis
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Psoriatic Arthritis
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer


List of Tables

- Psoriatic Arthritis Therapeutic Market, US, Marketed Drugs by Application Type, 2017
- Psoriatic Arthritis Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
- Psoriatic Arthritis Therapeutic Market, US, (Year), 2017
- Psoriatic Arthritis Marketed Drugs, API Manufacturers by US DMF Status, 2017
- Psoriatic Arthritis Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Psoriatic Arthritis Drugs, API Manufacturers, Europe by Country, 2017
- Psoriatic Arthritis Drugs, API Manufacturers, India by State, 2017
- Psoriatic Arthritis Drugs, API Manufacturers, China by Province, 2017
- Psoriatic Arthritis Drugs, API Manufacturers by Geography 2017
- Psoriatic Arthritis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Psoriatic Arthritis Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2017
- Phase III Drugs for Psoriatic Arthritis, 2017
- Discontinued Drugs for Psoriatic Arthritis, 2017


List of Figures

- Psoriatic Arthritis Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
- Psoriatic Arthritis Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
- Psoriatic Arthritis Therapeutic Market, US, (Year), 2017
- Psoriatic Arthritis Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
- Psoriatic Arthritis Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Psoriatic Arthritis Drugs, API Manufacturers, Europe by Country, 2017
- Psoriatic Arthritis Drugs, API Manufacturers, India by State, 2017
- Psoriatic Arthritis Drugs, API Manufacturers, China by Province, 2017
- Psoriatic Arthritis Drugs, API Manufacturers by Geography 2017
- Psoriatic Arthritis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Psoriatic Arthritis Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Global Scleroderma Diagnostics and Therapeutics Market: Overview Scleroderma, a very rare autoimmune disorder of the skin, is a term coined from the Greek words “sklerosis,” which means hardness, and ...

Ankylosing spondylitis (AS)- Market Insights, Epidemiology and Market Forecast-2023

Ankylosing spondylitis (AS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Ankylosing spondylitis (AS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Vitiligo - Market Insights, Epidemiology and Market Forecast-2023

Vitiligo - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Vitiligo - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


Download Unlimited Documents from Trusted Public Sources

Influenza Statistics in the US

  • February 2017
    9 pages
  • Influenza  

  • United States  

View report >

Autoimmune Disease Statistics in the US

  • February 2017
    9 pages
  • Autoimmune Dise...  

    Hospital  

  • United States  

View report >

Influenza Statistics in the US

  • February 2017
    9 pages
  • Influenza  

  • United States  

View report >

Chromosome Industry

13 days ago

Related Market Segments :

Autoimmune Disease
Cloud Computing

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.